Uncategorized

Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

EAGAN, MN — September 28, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s novel phase 2 cancer immunotherapy.  These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors.  The high profile late-breaking session of the AACR-NCI- EORTC will feature initial...

Read More


Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG

3 Poster Presentations Scheduled for Society for Immunotherapy of Cancer Annual Meeting EAGAN, MN — November 11, 2016 — Biothera Pharmaceuticals, Inc. will present new preclinical data today that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies. The data will be highlighted in three...

Read More